PT2874630T - Regime de dosagem para inibidores de janus quinase (jak) - Google Patents

Regime de dosagem para inibidores de janus quinase (jak)

Info

Publication number
PT2874630T
PT2874630T PT13742573T PT13742573T PT2874630T PT 2874630 T PT2874630 T PT 2874630T PT 13742573 T PT13742573 T PT 13742573T PT 13742573 T PT13742573 T PT 13742573T PT 2874630 T PT2874630 T PT 2874630T
Authority
PT
Portugal
Prior art keywords
jak
kinase inhibitors
janus kinase
dose scheme
inhibitors dose
Prior art date
Application number
PT13742573T
Other languages
English (en)
Portuguese (pt)
Inventor
J Gonzales Andrea
B Cosgrove Sallie
B Malpas Phyllis
Rolf Stegemann Michael
Turner Collard Wendy
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48901189&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2874630(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Publication of PT2874630T publication Critical patent/PT2874630T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
PT13742573T 2012-07-20 2013-07-18 Regime de dosagem para inibidores de janus quinase (jak) PT2874630T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261674289P 2012-07-20 2012-07-20
US201361815803P 2013-04-25 2013-04-25

Publications (1)

Publication Number Publication Date
PT2874630T true PT2874630T (pt) 2019-01-31

Family

ID=48901189

Family Applications (1)

Application Number Title Priority Date Filing Date
PT13742573T PT2874630T (pt) 2012-07-20 2013-07-18 Regime de dosagem para inibidores de janus quinase (jak)

Country Status (25)

Country Link
US (1) US9522151B2 (https=)
EP (1) EP2874630B1 (https=)
JP (2) JP6022063B2 (https=)
KR (2) KR20170034949A (https=)
CN (2) CN108354938A (https=)
AU (1) AU2013292547B2 (https=)
BR (1) BR112015000808A2 (https=)
CA (1) CA2878867C (https=)
CY (1) CY1121436T1 (https=)
DK (1) DK2874630T3 (https=)
ES (1) ES2707627T3 (https=)
HK (2) HK1209314A1 (https=)
HR (1) HRP20182088T1 (https=)
HU (1) HUE042771T2 (https=)
IN (1) IN2015DN00370A (https=)
LT (1) LT2874630T (https=)
MX (1) MX360857B (https=)
NZ (1) NZ703152A (https=)
PL (1) PL2874630T3 (https=)
PT (1) PT2874630T (https=)
RS (1) RS58242B1 (https=)
SI (1) SI2874630T1 (https=)
SM (1) SMT201900044T1 (https=)
WO (1) WO2014015107A1 (https=)
ZA (1) ZA201500134B (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP201606600B (en) 2013-02-22 2017-01-10 Pfizer Pyrrolo [2, 3 -d]pyrimidine derivatives as inhibitors of janus- related kinases (jak)
WO2016024185A1 (en) 2014-08-12 2016-02-18 Pfizer Inc. Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase
US12365689B2 (en) 2015-10-16 2025-07-22 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11773106B2 (en) 2015-10-16 2023-10-03 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
SG10201913990RA (en) 2015-10-16 2020-03-30 Abbvie Inc PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10973913B2 (en) 2016-02-16 2021-04-13 Washington University JAK inhibitors and uses thereof
CN107098908B (zh) * 2016-02-23 2021-01-08 欣凯医药科技(上海)有限公司 一种吡咯并嘧啶类化合物的制备方法和应用
KR102195348B1 (ko) 2018-11-15 2020-12-24 에이치케이이노엔 주식회사 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물
MX2021008984A (es) * 2019-01-30 2021-09-08 Felicamed Biotechnology Co Ltd Inhibidor jak y metodo de preparacion del mismo.
US11992490B2 (en) 2019-10-16 2024-05-28 Incyte Corporation Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP)
MX2023007150A (es) 2020-12-18 2023-09-04 Boehringer Ingelheim Animal Health Usa Inc Compuestos de pirazol que contienen boro, composiciones que los comprenden, métodos y usos de los mismos.
AU2022239128B2 (en) * 2021-03-16 2024-09-05 Hk Inno.N Corporation Novel salts of heterocyclic compound as protein kinase inhibitor and uses thereof
CA3216017A1 (en) * 2021-04-22 2022-10-27 Shengjian Huang Pharmaceutical composition containing jak3/jak1/tbk1 selective inhibitor and medical use thereof
WO2024259429A2 (en) * 2023-06-16 2024-12-19 The University Of Chicago Methods and compositions for pharmaceutically relevant interactions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK286640B6 (sk) 1998-06-19 2009-03-05 Pfizer Products Inc. Pyrol [2,3-d] pyrimidínová zlúčenina, jej použitie na výrobu liečiva, farmaceutická kompozícia s jej obsahom, použitie jej kombinácie s ďalšími činidlami a súpravy s jej obsahom na výrobu liečiva
KR101335843B1 (ko) 2008-08-20 2013-12-02 조에티스 엘엘씨 피롤로[2,3-d]피리미딘 화합물

Also Published As

Publication number Publication date
CA2878867C (en) 2018-01-09
HK1209314A1 (en) 2016-04-01
MX360857B (es) 2018-11-20
HRP20182088T1 (hr) 2019-02-08
KR20170034949A (ko) 2017-03-29
AU2013292547B2 (en) 2017-05-04
ES2707627T3 (es) 2019-04-04
PL2874630T3 (pl) 2019-04-30
CY1121436T1 (el) 2020-05-29
CA2878867A1 (en) 2014-01-23
WO2014015107A1 (en) 2014-01-23
AU2013292547A1 (en) 2015-01-22
CN104470525A (zh) 2015-03-25
NZ703152A (en) 2016-03-31
BR112015000808A2 (pt) 2017-06-27
EP2874630A1 (en) 2015-05-27
EP2874630B1 (en) 2018-12-05
JP2017019816A (ja) 2017-01-26
SI2874630T1 (sl) 2019-04-30
JP6022063B2 (ja) 2016-11-09
CN108354938A (zh) 2018-08-03
SMT201900044T1 (it) 2019-02-28
US9522151B2 (en) 2016-12-20
LT2874630T (lt) 2019-02-11
HK1252083A1 (zh) 2019-05-17
MX2015000871A (es) 2015-05-07
DK2874630T3 (en) 2019-01-28
HUE042771T2 (hu) 2019-07-29
RS58242B1 (sr) 2019-03-29
US20150126535A1 (en) 2015-05-07
JP2015522620A (ja) 2015-08-06
ZA201500134B (en) 2016-08-31
KR20150028299A (ko) 2015-03-13
IN2015DN00370A (https=) 2015-06-12

Similar Documents

Publication Publication Date Title
PT2874630T (pt) Regime de dosagem para inibidores de janus quinase (jak)
IL265007B (en) Pyrazolopyrimidine compounds as kinase inhibitors
DK2710007T3 (da) Kinasehæmmere
DK2903618T3 (da) Rho-kinase-inhibitorer
DK3303348T3 (da) Naphthyridinforbindelser som JAK-kinaseinhibitorer
DK3321262T3 (da) Serin-/threoninkinasehæmmere
CO6970602A2 (es) Inhibidores de quinasa
IL242453B (en) Bipyrazole derivatives as jak inhibitors
BR112015002709A2 (pt) novos compostos de pirrolopirimidina como inibidores de proteínas quinases
EP2863748A4 (en) 1,2,4-triazine-6-CARBOXAMIDKINASEINHIBITOREN
BR112014028424A2 (pt) compostos de pirimidina para o tratamento de câncer
EP2900668A4 (en) INHIBITORS OF MULTIPLE KINASE PATHWAYS
CO6880068A2 (es) Aminoquinazolinas como inhibidores de quinasa
DK2917210T3 (da) Alk kinase-inhibitorer
BR112015005361A2 (pt) inibidores de tirosina quinase de bruton
PL2634185T3 (pl) Inhibitory kinazy TYK2
IL228567A0 (en) Imidazopyridazines as akt kinase inhibitors
SG11201500973WA (en) Amino-quinolines as kinase inhibitors
CO6990735A2 (es) Inhibidores de pirazina cinasa
EP2968358A4 (en) NOVEL CHOLINKINASE INHIBITORS
HUE036347T2 (hu) Aminokinazolin-kináz-inhibitor prodrogjai
BR112014033056A2 (pt) inibidores da proteína quinase
BR112014029718A2 (pt) inibidores da proteína quinase
AP2015008532A0 (en) Syk kinase inhibitors as treatment for malaria